Advances in Diagnosis and Treatment of Prostate Cancer
A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Biomedical Engineering and Biomaterials".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 3752
Special Issue Editors
2. Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
Interests: prostate cancer treatment; nanotechnology; targeted treatment; radiosensitization; drug delivery; nanoparticles
Special Issues, Collections and Topics in MDPI journals
Interests: radiation; brain tumor; biomarkers
Interests: transcription; metabolism; tumor microenvironment
Interests: biomarker discovery; proteomics; biomaterials; cancer research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Prostate cancer is the second most diagnosed cancer and the fifth leading cause of cancer death among men worldwide, with an estimated 1,414,000 new cancer cases and 375,304 deaths in 2020. Although it often has an indolent course, prostate cancer remains the leading cause of cancer death in men. Although tissue biopsy remains the standard of care for diagnosis, the identification and characterization of the disease have become increasingly personalized through advances in functional and molecular imaging modalities (e.g., MRI, PET, SPECT), as well as from the emergence of biomarkers. In particular, prostate-specific membrane antigen (PSMA), in general, is overexpressed in prostate cancers in proportion to aggressiveness, and as tracers of PET, SPECT has been shown to be superior to a number of other tracers in identifying the local and metastatic sites of disease. Targeting PSMA is also proving efficacious in treatment when anti-PSMA ligands are conjugated to radiolabeled elements such as lutetium-177, yttrium-90, iridium-192, gold-198, ytterbium-169, etc. Recent advances in the synthesis of nanomaterials with diagnostic and therapeutic capabilities have been rapidly reshaping the landscape of precision medicine specific to prostate cancer. Active targeting nanocarriers are versatile platforms which synergistically integrate diagnosis and multiple therapy strategies, including chemotherapy, radiotherapy, immunotherapy, photodynamic therapy, etc. This Special Issue of Bioengineering aims to provide multiple perspectives on the advances in diagnosis and treatment of prostate cancer by bringing together worldwide contributions on the clinical and pre-clinical studies of targeted imaging and therapy for prostate cancer.
Dr. Junwei Shi
Dr. Wensi Tao
Dr. Eriko Katsuta
Prof. Dr. Yu-Chang Tyan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- chemotherapy
- radiation therapy
- immunotherapy
- photothermal therapy
- functional imaging
- molecular imaging
- radiopharmaceuticals
- prostate-specific membrane antigen (PSMA)
- nanomedicine
- active targeting
- clinical
- pre-clinical
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.